Sponsor

Avistone Biotechnology Co., Ltd.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Avistone Biotechnology Co., Ltd. appears in 11 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials11
Recruiting shown5
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

11 shown
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung CancerNCT07538804 · lead sponsor · 2026-07-10
RECRUITING
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR MutationsNCT07336732 · lead sponsor · 2026-03-11
RECRUITING
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.NCT06574347 · lead sponsor · 2024-08-07
RECRUITING
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung CancerNCT06046495 · lead sponsor · 2024-07-08
RECRUITING
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKINCT06343064 · lead sponsor · 2023-06-13
RECRUITING
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI FailureNCT06970782 · lead sponsor · 2025-05-15
NOT_YET_RECRUITING
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.NCT06281964 · lead sponsor · 2023-12-01
ENROLLING_BY_INVITATION
A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)NCT06015503 · lead sponsor · 2023-07-21
ACTIVE_NOT_RECRUITING
Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT05347628 · lead sponsor · 2020-08-25
UNKNOWN
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung CancerNCT07285148 · collaborator · 2026-06-01
NOT_YET_RECRUITING
Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLCNCT06827145 · collaborator · 2024-10-14
ACTIVE_NOT_RECRUITING

Drugs studied in this sponsor's trials

1 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Avistone Biotechnology Co., Ltd. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Sponsor roles

lead sponsor9
collaborator2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.